Synopsis
The organisers invite you to the 23rd SCI-RSC Medicinal Chemistry symposium, Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry. Reflecting current trends in medicinal chemistry and pharmaceutical research, the scientific programme will feature lectures on the full range of drug targets, key enabling processes and technologies.
Workshop
The workshop is based on an interactive, team-based game that allows you to explore various aspects of the drug discovery process. Delegates will work together in teams with peers from other organisations and the learning experience will be facilitated by a dedicated and diverse team of experienced professional medicinal chemists from across the pharmaceutical industry. This is a great way to accelerate your learning curve in medicinal chemistry, learning from your peers and our experts and it’s a lot of fun to play.
Attendees
This conference will be of interest to both academic and industrial scientists engaged in all aspects of the drug discovery and development process.
The separate workshop will be of interest to early career scientists, typically with five years or fewer post-graduate experience in medicinal chemistry.
Programme
To view the full programme click
here.
Call for abstracts
To view the call for abstracts, click
here.
Exhibition and sponsorship
For further information click
here.
Accessibility Grants
SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.
Venue and Contact
Fees
To see the delegate fees and to register (when available) please click here.
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Organising Committee
John Cumming, Roche
Mark Healy, Novartis
Daniel O Donovan, AstraZeneca
Joanne Pinder, Vertex
Jamie Scott, AstraZeneca
Gordon Saxty, NS-MC Consulting
Chris Swain, Cambridge MedChem Consulting
Andrew Williams, Chairman of the RSC BMCS